Article Text

PDF
Extended report
Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease
  1. Jon T Giles1,
  2. Sonye K Danoff2,
  3. Jeremy Sokolove3,4,
  4. Catriona A Wagner3,4,
  5. Robert Winchester1,
  6. Dimitrios A Pappas1,
  7. Stanley Siegelman2,
  8. Geoff Connors5,
  9. William H Robinson3,4,
  10. Joan M Bathon1
  1. 1Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, New York, USA
  2. 2Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA
  3. 3Veterans Administration Palo Alto Health Care System, Palo Alto, California, USA
  4. 4Division of Rheumatology, Stanford University, Stanford, California, USA
  5. 5Division of Pulmonary and Critical Care Medicine, Yale University, New Haven, Connecticut, USA
  1. Correspondence to Dr J T Giles, Division of Rheumatology, Columbia University, College of Physicians and Surgeons, 630 W 168th St, Physicians and Surgeons Building, Suite 10-445, New York, NY 10032, USA; jtg2122{at}columbia.edu

Abstract

Background Interstitial lung disease (ILD) is associated with high morbidity and mortality in rheumatoid arthritis (RA). Citrullinated proteins are observed in RA lung tissues; however, the association of specific anticitrullinated peptide antibodies (ACPA) with ILD in RA is unknown.

Methods RA patients underwent multidetector CT (MDCT) of the chest, from which ILD features and a semiquantitative ILD Score (ILDS; range 0–32) were assessed. Anti-CCP (CCP2) and levels of a panel of antibodies against 17 citrullinated and four non-citrullinated peptides were assessed from concurrent serum samples using a custom Bio-Plex bead array. High level ACPA was defined as ≥the group 75th percentile.

Results Among the 177 RA patients studied, median levels of CCP2 and all specific ACPAs were 46–273% higher among RA patients with versus those without ILD (all p values <0.05), and higher levels correlated with higher ILDS. In contrast, levels of non-citrullinated protein antibodies were not higher in those with ILD. RA patients had a median of 2 high level ACPA reactivities (range 0–16), with each high level ACPA associated, on average, with a 0.10 unit higher ILDS (p=0.001). This association remained significant after adjusting for characteristics associated with ILD (age, gender, current and former smoking, Disease Activity Score for 28 joints, current prednisone and leflunomide use). More high level ACPA were observed in those with versus without pulmonary function restriction or impaired diffusion.

Conclusions Our findings of a broader ACPA repertoire in RA ILD suggest a possible role for ACPA in the pathogenesis of ILD.

  • Rheumatoid Arthritis
  • Ant-CCP
  • Autoantibodies

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.